Entering a new market, Molecular Devices has acquired the laser capture microdissection (LCM) business of Arcturus Biosicence for $10 million in cash.

The acquisition pushes Molecular Devices into the sample preparation products arena and puts the company in competition with other LCM tool providers, such as Leica Microsystems, Molecular Machines & Industries (MMI), and Carl Zeiss, which has an alliance for the technology with BCW Index firm Qiagen.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.